Type II Vasoactive Intestinal Peptide Receptors

A pituitary adenylate cyclase-activating peptide receptor subtype found in LYMPHOCYTES. It binds both PACAP and VASOACTIVE INTESTINAL PEPTIDE and regulates immune responses.
Also Known As:
Receptors, Vasoactive Intestinal Peptide, Type II; PACAP Receptors, Type III; PACAP Type III Receptor; PACAPR-3 Protein; VIP2 Receptor; VIP2 Receptors; VIPR2 Protein; VPAC2 Receptor; Vasoactive Intestinal Peptide 2 Receptor; Vasoactive Intestinal Peptide Receptor 2; PACAPR 3 Protein; Pituitary Adenylate Cyclase Activating Peptide Receptor Type III; Receptor, VIP2; Receptor, VPAC2; Receptors, VIP2; Pituitary Adenylate Cyclase-Activating Peptide Receptor Type III; Receptors, Pituitary Adenylate Cyclase-Activating Peptide, Type III; VIP Receptors, Type II; Vasoactive Intestinal Peptide Receptors, Type II
Networked: 17 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Gledhill, John M: 1 article (12/2015)
2. Clark, Barbara E: 1 article (12/2015)
3. Anderson, Kristi M: 1 article (12/2015)
4. Shandler, Scott J: 1 article (12/2015)
5. Diggs, Breha J: 1 article (12/2015)
6. Gendelman, Howard E: 1 article (12/2015)
7. Mosley, R Lee: 1 article (12/2015)
8. Olson, Katherine E: 1 article (12/2015)
9. Kosloski-Bilek, Lisa M: 1 article (12/2015)
10. Bannerman, David M: 1 article (01/2015)

Related Diseases

1. Stroke (Strokes)
2. Schizophrenia (Dementia Praecox)
3. Myopia
4. Genetic Predisposition to Disease (Genetic Predisposition)
5. Post-Traumatic Stress Disorders (PTSD)

Related Drugs and Biologics

1. Lys(15)-Arg(16)-Leu(27)- vasoactive intestinal peptide (1-7)-GRF (8-27)
2. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
3. Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
4. Type I Vasoactive Intestinal Polypeptide Receptors
5. Cholecystokinin B Receptor
6. Neuregulin-1 (Neuregulin 1)
7. Monocrotaline
8. Antipsychotic Agents (Antipsychotics)
9. Proteins (Proteins, Gene)
10. Cyclic AMP (AMP, Cyclic)